AstraZeneca (AZN) has cancelled a plan to invest 450 million pounds ($558.3 million) in a UK vaccine manufacturing plant in Liverpool.
Reduced UK government support is the main reason for withdrawing from the Speke facility development, the company said.
"Several factors have influenced this decision, including the timing and reduction of the final offer compared to the previous government's proposal," a company spokesperson said.
Despite the change in plans, the plant in Liverpool will continue to produce the company's flu vaccine, AstraZeneca said.
Price: 70.92, Change: -0.32, Percent Change: -0.45
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。